SM
BHVN

Sabby Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Sabby Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-19,850
Closed -$828K – 110
2019
Q3 		$828K Buy
+19,850
New +$839K 0.45% 27

Other funds holding BHVN

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sabby Management's BHVN Position: Q4 2019 in Review

Sabby Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2019, closing a stake of 19,850 shares — an estimated $828K sold.

Sabby Management first reported a position in BHVN in Q3 2019 and held it in 1 quarter. The position peaked at $828K in Q3 2019. 188 funds tracked by Wall St. Rank hold BHVN as of Q4 2019.

  • Sabby Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2019 after selling out during the quarter.
  • Sabby Management sold 19,850 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2019, an estimated $828K.
  • Sabby Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2019 and held it in 1 quarter.
  • Sabby Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $828K in Q3 2019.
  • 188 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2019.

Based on Sabby Management's 13F filing for Q4 2019, filed 14 Feb 2020.